The acquisition will further build out Merck’s pipeline of next-generation immunotherapies as its top-seller Keytruda nears the end of U.S. market exclusivity.Dive Brief:Merck & Co. is beefing up its cancer pipeline, announcing Monday it will pay $680 million to buy Harpoon Therapeutics for its armory of dual-acting immunotherapies targeting lung, abdominal and blood cancers.Merck agreed […]
